(5-chloro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride | 202807-65-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (5-chloro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride
• 英文别名: 2-(5-Chloro-1-methylindol-3-yl)-2-oxoacetyl chloride
• CAS: 202807-65-6
• 化学式: C₁₁H₇Cl₂NO₂
• 分子量: 256.088
• InChiKey: QBQCDHCCEVMSHU-UHFFFAOYSA-N

物化性质

• 沸点：
  425.0±48.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  39.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5-chloro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride 在 ammonium hydroxide 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 Bisindolylmaleimide deriv. 28
  参考文献：
  名称：

  Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides

  摘要：

  The design and synthesis of a series of novel inhibitors of protein kinase C (PKC) is described. These 2,3-bisarylznaleimides were derived from the structural lead provided by the indolocarbazoles, staurosporine and K252a. Optimum activity required the imide NH, both carbonyl groups, and the olefinic bond of the maleimide ring. 2,3-Bisindolylmaleimides were the most active, and the potency of these was improved by a chloro substituent at the 5-position of one indole ring (compound 28, IC50 0.11-mu-M). In a series of (phenylindolyl)maleimides, nitro compound 74 was most active (IC50 0.67-mu-M). Naphthalene 19 and benzothiophene 21 showed greater than 100-fold selectivity for inhibition of PKC over the closely related cAMP-dependent protein kinase (PKA).

  DOI：

  10.1021/jm00079a024
• 作为产物：
  描述：

  5-氯吲哚 在 sodium hydride 作用下， 以 二氯甲烷 为溶剂， 反应 19.5h， 生成 (5-chloro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride
  参考文献：
  名称：

  Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides

  摘要：

  The design and synthesis of a series of novel inhibitors of protein kinase C (PKC) is described. These 2,3-bisarylznaleimides were derived from the structural lead provided by the indolocarbazoles, staurosporine and K252a. Optimum activity required the imide NH, both carbonyl groups, and the olefinic bond of the maleimide ring. 2,3-Bisindolylmaleimides were the most active, and the potency of these was improved by a chloro substituent at the 5-position of one indole ring (compound 28, IC50 0.11-mu-M). In a series of (phenylindolyl)maleimides, nitro compound 74 was most active (IC50 0.67-mu-M). Naphthalene 19 and benzothiophene 21 showed greater than 100-fold selectivity for inhibition of PKC over the closely related cAMP-dependent protein kinase (PKA).

  DOI：

  10.1021/jm00079a024

文献信息

• 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
  申请人：——

  公开号：US20020052397A1

  公开（公告）日：2002-05-02

  This invention relates to inhibitors of glycogen synthase kinase- 3 &bgr;, methods of treating diseases characterized by an excess of Th 2 cytokines, and to 3 -indolyl- 4 -phenyl- 1 H-pyrrole- 2,5 -dione derivatives of Formula (I): 1 that are inhibitors of glycogen synthase kinase - 3 &bgr;, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

  这项发明涉及抑制糖原合成酶激酶-3β的方法，用于治疗由Th2细胞因子过多引起的疾病，以及3-吲哚基-4-苯基-1H-吡咯-2,5-二酮衍生物的化合物(I)的方法：这些化合物是糖原合成酶激酶-3β的抑制剂，包含它们的药物组合物，使用它们的方法以及制备这些化合物的方法。
• Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3 betta
  申请人：Syntex (U.S.A.) LLC

  公开号：US20030176484A1

  公开（公告）日：2003-09-18

  This invention relates to the use of inhibitors of glycogen synthase kinase-3&bgr; to increase bone formation.

  这项发明涉及利用糖原合成激酶-3β抑制剂来增加骨形成。
• Substituted pyrroles
  申请人：Hoffmann-La Roche Inc.

  公开号：US06228877B1

  公开（公告）日：2001-05-08

  Compounds of the formula wherein R1 and R1′ are independently alkyl, aryl, alkenyl or alkynyl; R2 and R2′ are independently hydrogen, alkyl, aralkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, acylaminoalkyl, alkylsulphonylaminoalkyl, arylsulphonyl-aminoalkyl, mercaptoalkyl, alkylthioalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylthio or alkylsulphinyl; R4, R5, R6, R7, R4′, R5′, R6′, and R7′ each independently are hydrogen, CO2R9, CH2OR10, CHO, CH2NR11R12, CON(R13)2, halogen, cyano, aryl, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, aralkyloxy, acylamino, monoalkylamino, dialkylamino, thio, alkyl, alkylsulphinyl, alkylsulphonyl, arylsulphinyl, azide, phosphate or phosphonate provided that at least one of R4, R5, R6 and R7 and at least one of R4′, R5′, R6′, and R7′ are other than hydrogen, with the proviso that when R6 is methoxy, R5 or R5′ are not methoxy; R8 is alkyl or aryl; R9 is alkyl or aryl; R10 is hydrogen, alkyl or aryl; R11 and R12 are independently hydrogen, alkyl, aryl, aralkyl or acyl; R13 is hydrogen, alkyl, aryl or aralkyl; and one of X and Y signifies O and the other signifies O, S, (H,OH) or (H,H); as well as pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts of acidic compounds of formula I with bases and or basic compounds of formula I with acids are antiproliferative agents useful in the treatment of cancer.

  化合物的公式为其中R1和R1'分别独立地为烷基、芳基、烯基或炔基；R2和R2'分别独立地为氢、烷基、芳基烷基、烷氧基烷基、羟基烷基、卤代烷基、氨基烷基、单烷基氨基烷基、双烷基氨基烷基、酰胺基烷基、烷基磺酰胺基烷基、芳基磺酰胺基烷基、巯基烷基、烷硫基烷基、羧基烷基、烷氧羰基烷基、氨基羰基烷基、烷硫基或烷基亚磺酰基；R4、R5、R6、R7、R4'、R5'、R6'和R7'各自独立地为氢、CO2R9、CH2OR10、CHO、CH2NR11R12、CON(R13)2、卤素、氰基、芳基、烷基、羟基、烷氧基、芳氧基、卤代烷基、硝基、氨基、芳基氧基、酰胺基、单烷基氨基、双烷基氨基、硫基、烷基、烷基亚磺酰基、烷基磺酰基、芳基亚磺酰基、偶氮基、磷酸酯或膦酸酯，但至少有R4、R5、R6和R7中的一个和R4'、R5'、R6'和R7'中的一个不是氢，如果R6是甲氧基，则R5或R5'不是甲氧基；R8为烷基或芳基；R9为烷基或芳基；R10为氢、烷基或芳基；R11和R12独立地为氢、烷基、芳基、芳基烷基或酰基；R13为氢、烷基、芳基或芳基烷基；X和Y中的一个表示O，另一个表示O、S、(H,OH)或(H,H)；以及公式I的酸性化合物的药学上可接受的前药或与酸的公式I的碱性化合物的药学上可接受的盐是抗增殖剂，可用于癌症的治疗。
• Structural Manipulations of Marine Natural Products Inspire a New Library of 3-Amino-1,2,4-Triazine PDK Inhibitors Endowed with Antitumor Activity in Pancreatic Ductal Adenocarcinoma
  作者：Daniela Carbone、Michele De Franco、Camilla Pecoraro、Davide Bassani、Matteo Pavan、Stella Cascioferro、Barbara Parrino、Girolamo Cirrincione、Stefano Dall’Acqua、Stefania Sut、Stefano Moro、Valentina Gandin、Patrizia Diana

  DOI：10.3390/md21050288

  日期：——

  Pancreatic ductal adenocarcinoma (PDAC) is one of the main aggressive types of cancer, characterized by late prognosis and drug resistance. Among the main factors sustaining PDAC progression, the alteration of cell metabolism has emerged to have a key role in PDAC cell proliferation, invasion, and resistance to standard chemotherapeutic agents. Taking into account all these factors and the urgency in evaluating novel options to treat PDAC, in the present work we reported the synthesis of a new series of indolyl-7-azaindolyl triazine compounds inspired by marine bis-indolyl alkaloids. We first assessed the ability of the new triazine compounds to inhibit the enzymatic activity of pyruvate dehydrogenase kinases (PDKs). The results showed that most of derivatives totally inhibit PDK1 and PDK4. Molecular docking analysis was executed to predict the possible binding mode of these derivatives using ligand-based homology modeling technique. Evaluation of the capability of new triazines to inhibit the cell growth in 2D and 3D KRAS-wild-type (BxPC-3) and KRAS-mutant (PSN-1) PDAC cell line, was carried out. The results showed the capacity of the new derivatives to reduce cell growth with a major selectivity against KRAS-mutant PDAC PSN-1 on both cell models. These data demonstrated that the new triazine derivatives target PDK1 enzymatic activity and exhibit cytotoxic effects on 2D and 3D PDAC cell models, thus encouraging further structure manipulation for analogs development against PDAC.

  胰腺导管腺癌（PDAC）是主要的侵袭性癌症类型之一，具有预后晚和耐药性强的特点。在维持 PDAC 进展的主要因素中，细胞新陈代谢的改变已成为 PDAC 细胞增殖、侵袭和对标准化疗药物产生耐药性的关键因素。考虑到所有这些因素以及评估治疗 PDAC 的新方案的紧迫性，我们在本研究中报告了受海洋双吲哚生物碱启发合成的一系列新的吲哚基-7-氮杂吲哚基三嗪化合物。我们首先评估了新三嗪化合物抑制丙酮酸脱氢酶激酶（PDKs）酶活性的能力。结果表明，大多数衍生物能完全抑制 PDK1 和 PDK4。利用基于配体的同源建模技术进行了分子对接分析，以预测这些衍生物可能的结合模式。研究还评估了新型三嗪类化合物在二维和三维 KRAS 野生型（BxPC-3）和 KRAS 突变型（PSN-1）PDAC 细胞系中抑制细胞生长的能力。结果表明，新衍生物能够降低两种细胞模型中 KRAS 突变型 PDAC PSN-1 的细胞生长，并对其具有较大的选择性。这些数据表明，新的三嗪衍生物以 PDK1 酶活性为靶点，在二维和三维 PDAC 细胞模型上表现出细胞毒性作用，从而鼓励了针对 PDAC 类似物开发的进一步结构操作。
• Discovery of potent and bioavailable GSK-3β inhibitors
  作者：Leyi Gong、Don Hirschfeld、Yun-Chou Tan、J. Heather Hogg、Gary Peltz、Zafrira Avnur、Pete Dunten

  DOI：10.1016/j.bmcl.2010.01.038

  日期：2010.3

  Here we report on the discovery of a series of maleimides which have high potency and good selectivity for GSK-3 beta. The incorporation of polar groups afforded compounds with good bioavailability. The most potent compound 34 has an IC(50) of 0.6 nM for GSK-3 beta, over 100-fold selectivity against a panel of other kinases, and shows efficacy in rat osteoporosis models. The X-ray structure of GSK-3 beta protein with 34 bound revealed the binding mode of the template and provided insights for future optimization opportunities. (C) 2010 Elsevier Ltd. All rights reserved.